BridgeBio (BBIO, Financial) has received a positive boost from H.C. Wainwright as the analyst Raghuram Selvaraju raised the stock's price target to $53, up from the previous $49. The firm maintains a Buy rating for the company.
The update comes amid encouraging receptivity for the company's drug, acoramidis. This development suggests a favorable outlook for BridgeBio's market performance and future prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for BridgeBio Pharma Inc (BBIO, Financial) is $55.27 with a high estimate of $95.00 and a low estimate of $37.00. The average target implies an upside of 58.58% from the current price of $34.85. More detailed estimate data can be found on the BridgeBio Pharma Inc (BBIO) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, BridgeBio Pharma Inc's (BBIO, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for BridgeBio Pharma Inc (BBIO, Financial) in one year is $42.40, suggesting a upside of 21.66% from the current price of $34.85. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BridgeBio Pharma Inc (BBIO) Summary page.
